(Q54482424)

30 May 2018

title

Inhibition of ocular neovascularization by a novel peptide derived from human placenta growth factor-1. (English)

1 reference

30 May 2018

1 reference

Ying Zheng

1

1 reference

30 May 2018

Qing Gu

series ordinal

2

1 reference

30 May 2018

Xun Xu

series ordinal

3

1 reference

30 May 2018

publication date

20 September 2012

1 reference

30 May 2018

published in

Acta Ophthalmologica

1 reference

30 May 2018

volume

90

1 reference

30 May 2018

issue

7

1 reference

30 May 2018

page(s)

e512-23

1 reference

30 May 2018

Therapeutic application of peptides and proteins: parenteral forever?

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2012.02476.X

The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2012.02476.X

Angiogenesis in cancer and other diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2012.02476.X

Comparative effects of bevacizumab, ranibizumab and pegaptanib at intravitreal dose range on endothelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2012.02476.X

The crystal structure of placental growth factor in complex with domain 2 of vascular endothelial growth factor receptor-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2012.02476.X

Retinal and choroidal angiogenesis: pathophysiology and strategies for inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2012.02476.X

Identification of placenta growth factor determinants for binding and activation of Flt-1 receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2012.02476.X

Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2012.02476.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2012.02476.X

A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2012.02476.X

Pegaptanib for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2012.02476.X

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2012.02476.X

Preclinical safety evaluation of intravitreal injection of full-length humanized vascular endothelial growth factor antibody in rabbit eyes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2012.02476.X

The crystal structure of human placenta growth factor-1 (PlGF-1), an angiogenic protein, at 2.0 A resolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2012.02476.X

A study of the ability of tissue plasminogen activator to diffuse into the subretinal space after intravitreal injection in rabbits.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2012.02476.X

Apelin is a novel angiogenic factor in retinal endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2012.02476.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2012.02476.X

Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2012.02476.X

Standard for clinical electroretinography (2004 update).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2012.02476.X

Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2012.02476.X

Review of ranibizumab trials for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2012.02476.X

The discovery of the placental growth factor and its role in angiogenesis: a historical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2012.02476.X

Developing antiangiogenic peptide drugs for angiogenesis-related diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2012.02476.X

VEGF and PlGF: two pleiotropic growth factors with distinct roles in development and homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2012.02476.X

RACK1 regulates VEGF/Flt1-mediated cell migration via activation of a PI3K/Akt pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2012.02476.X

Strategies to improve plasma half life time of peptide and protein drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2012.02476.X

Inhibitors of ocular neovascularization: promises and potential problems.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2012.02476.X

Ultra-performance LC/TOF MS analysis of medicinal Panax herbs for metabolomic research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2012.02476.X

A novel peptide from human apolipoprotein(a) inhibits angiogenesis and tumor growth by targeting c-Src phosphorylation in VEGF-induced human umbilical endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2012.02476.X

Ocular neovascularization: Implication of endogenous angiogenic inhibitors and potential therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2012.02476.X

Inhibition of pathologic retinal neovascularization by a small peptide derived from human apolipoprotein(a).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2012.02476.X

10.1111/J.1755-3768.2012.02476.X

21 January 2018

Identifiers

DOI

1 reference

30 May 2018

1 reference

30 May 2018